precisionmedicineonline23h
Cel-Sci to Initiate Phase III Trial of Immunotherapy in PD-L1-Low Head and Neck Cancer
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
EQS-News: Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
EQS-News: GeoVax, Inc. / Key word (s): Financial Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification 19.02.2025 / 15:04 CET/CEST The issuer is solely responsible for the ...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...